FBIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Fortress Biotech Inc (FBIO) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the technical indicators show some bullish signals, the lack of significant positive catalysts, declining financial performance, and neutral sentiment from hedge funds and insiders suggest that it is better to hold off on making a purchase right now.
The MACD is positive but contracting, RSI is neutral at 53.124, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 3.343, with resistance at 3.683 and support at 3.003. However, the regular market change of -4.90% indicates short-term weakness.
Alliance Global analyst raised the price target to $4.50 from $4 and maintained a Buy rating. Revenue increased by 20.52% YoY in Q3 2025.
Net income dropped by -124.43% YoY, EPS fell by -114.47% YoY, and gross margin declined by -3.99%. No recent news or significant trading activity from hedge funds, insiders, or Congress.
In Q3 2025, revenue grew by 20.52% YoY to $17.63M, but net income dropped significantly by -124.43% YoY to $3.68M. EPS also declined by -114.47% YoY to 0.11, and gross margin fell to 61.32%, down -3.99% YoY. This indicates worsening profitability despite revenue growth.
Alliance Global analyst Scott Henry raised the price target to $4.50 from $4 and maintained a Buy rating, citing lower operating expenses after the absence of Checkpoint.
